A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy (DICI_PC)

Soon Chun Hyang University

Status and phase

Not yet enrolling

Phase 2

Phase 1

Conditions

Pancreas Cancer

Treatments

Drug: dentritic cell infusion and immunecheckpoint inhibitor

Study type

Interventional

Funder types

Other

Identifiers

NCT06172634

DC_ICI_PC_1

Details and patient eligibility

About

To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one standard anticancer treatment.

Full description

After a test subject agrees in writing to participate in a clinical study, if he or she is determined to fit the selection criteria and does not meet the exclusion criteria through a screening process, he or she is enrolled in the clinical study.

After consenting to the study, subjects set a bone marrow collection date within 7 days of registration, and granulocyte colony-stimulating factor (G-CSF) is administered the day before bone marrow collection. After bone marrow collection (approximately 30-50 ml) on the day of bone marrow collection, autologous bone marrow-derived dendritic cells (Cellgram-DC-WT1) made by isolating CD141+ cells from the bone marrow are administered intravenously together with pembrolizumab, at 3-week intervals. After repeating the test drug administration 3 times at 3-week intervals, a radiological response evaluation of the tumor is performed, and a decision is made to continue or terminate the test drug administration according to the response evaluation results. If the response evaluation results for the tumor fall into a complete response, partial response, or stable disease, administration of the test drug is continued, and the response evaluation is repeated three times at three-week intervals. If the response evaluation result for the tumor is progressive disease, administration of the test drug is terminated.

Enrollment

10 estimated patients

Sex

All

Ages

19 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients histologically confirmed to have pancreatic cancer and diagnosed as recurrent or metastatic
Patients whose disease was confirmed to have progressed according to RECIST v1.1 after 1st or more standard anticancer treatments
Patients satisfying systemic performance status ECOG 0-2
Patients who have not undergone surgery, radiation therapy, or immunotherapy within 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the test subject's condition are permitted at the discretion of the researcher.)
Patients who voluntarily agreed in writing to participate in this clinical study

Exclusion criteria

Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
Patients who have previously received anti-tumor immunotherapy (anti-PD1, anti-PDL-1, or CTLA4 inhibitor, etc.) or participated in clinical studies related to immunotherapy or cell therapy
Patients with active autoimmune disease requiring systemic immunosuppressive treatment
Patients with a history of organ or hematopoietic stem cell transplantation
Patients with acute or chronic infection requiring systemic treatment
Other cases where the test manager determines that it is not suitable for clinical research